Your serum zinc level is not set only by diet. A common variant in the PPCDC gene¹¹ PPCDC gene
Phosphopantothenoylcysteine decarboxylase, an enzyme that catalyses the fifth step of coenzyme A biosynthesis from pantothenic acid (vitamin B5) influences how much zinc circulates in your blood, independently of how much you consume. Carriers of the C allele at rs2120019 tend to have lower serum zinc on average, an effect large enough to be genome-wide significant and consistently replicated as a genetic instrument in Mendelian randomization studies of zinc's role in cardiometabolic and infectious disease.

The Mechanism

PPCDC is not itself a zinc transporter. It encodes an enzyme in the coenzyme A (CoA) biosynthesis pathway²² coenzyme A (CoA) biosynthesis pathway
CoA is an essential cofactor in more than 100 enzymatic reactions including fatty acid synthesis, the citric acid cycle, and amino acid catabolism — converting 4'-phosphopantothenoylcysteine to 4'-phosphopantetheine. The intronic rs2120019 variant does not alter the PPCDC protein directly. Instead, the proposed mechanism is indirect: PPCDC variation may affect pantothenate metabolite pools, which in turn influence the expression or activity of downstream zinc homeostasis proteins, including zinc transporters expressed in the intestine and liver.

This mechanistic link remains incompletely characterized — the original GWAS authors acknowledged that "other genetic variation in the CoA synthesis pathway, specifically in PPCDC, could also lead to variation in Zn metabolism," while cautioning that this "cannot be taken further with current data." The association is robust at the epidemiological level (genome-wide significant, replicated across cohorts) even while the precise biochemical pathway is still under investigation.

The Evidence

The primary evidence comes from a genome-wide association study in 5,477 adults³³ genome-wide association study in 5,477 adults
Evans DM et al. Genome-wide association study identifies loci affecting blood copper, selenium and zinc. Hum Mol Genet, 2013 from the QIMR cohort (Australian twins and families) and the ALSPAC cohort (UK pregnant women). The rs2120019 C allele was associated with lower blood zinc at P = 1.55 × 10⁻¹⁸ (β = −0.287, SE = 0.033 standard deviations per C allele). This locus on chromosome 15 was one of only three genome-wide significant zinc signals identified, alongside chromosome 8 (near carbonic anhydrase genes) and chromosome X.

rs2120019 has subsequently been used as a standard genetic instrument in multiple Mendelian randomization studies. A 2018 two-sample MR study⁴⁴ 2018 two-sample MR study
Thun GA et al. Effects of copper and zinc on ischemic heart disease and myocardial infarction: a Mendelian randomization study. Am J Clin Nutr, 2018 found that the zinc instruments (including rs2120019) together explained ≥8% of variance in erythrocyte zinc and showed genetically instrumented higher zinc was associated with a modest increase in ischemic heart disease risk (OR 1.06; 95% CI 1.02–1.11). This counterintuitive finding — often interpreted as reflecting the U-shaped nature of zinc biology, where both deficiency and excess can be harmful — underscores that simply supplementing zinc indiscriminately is not appropriate even for lower-zinc genotypes.

In COVID-19 research, Moghaddam et al. 2021⁵⁵ Moghaddam et al. 2021
Association of Vitamin D, Zinc and Selenium Related Genetic Variants With COVID-19 Disease Severity. Front Nutr, 2021 included rs2120019 as the representative zinc genetic marker, while a larger MR analysis (Li et al. 2022⁶⁶ Li et al. 2022
Genetically Predicted Circulating Concentrations of Micronutrients and COVID-19 Susceptibility and Severity. Front Nutr, 2022) found limited evidence that genetically predicted zinc levels causally affect COVID-19 outcomes (OR 1.06 for hospitalization, 95% CI 0.81–1.39, p=0.66).

Practical Actions

The C allele at rs2120019 nudges serum zinc downward by roughly a quarter to a third of a standard deviation per copy. For a CC homozygote, this represents a meaningful shift in baseline zinc status that is worth accounting for in diet and monitoring — but does not require aggressive supplementation. Zinc is measured in serum or plasma; levels below 70 µg/dL in adults suggest inadequacy.

The best dietary sources of bioavailable zinc are shellfish (especially oysters), red meat, poultry, and legumes. Phytates in whole grains and legumes reduce zinc absorption, so soaking, sprouting, or fermenting these foods improves bioavailability. Supplemental zinc citrate and zinc gluconate are both absorbed at approximately 60%; zinc oxide has lower absorption at around 50%.

Avoid supplementing beyond 25 mg elemental zinc daily without confirmed deficiency — excess zinc can deplete copper, impair immune function, and, based on Mendelian randomization data, may be associated with elevated cardiovascular risk at the higher end of the zinc distribution.

Interactions

rs2120019 is one of three established zinc GWAS loci. The other two — rs1532423 (chromosome 8, near carbonic anhydrase genes) and rs11638477 (also associated with zinc) — are independent signals with separate mechanisms. Carrying the zinc-lowering allele at more than one of these loci would compound the downward shift in baseline zinc status, increasing the relevance of dietary zinc optimization and periodic monitoring.

Zinc bioavailability interacts with dietary copper: high-zinc supplementation competes with copper absorption, and vice versa. Users with both zinc-lowering and copper-altering variants should assess both minerals together rather than supplementing either in isolation.

Rheumatoid arthritis (RA) is driven by the chronic overactivation of NF-κB¹¹ NF-κB
Nuclear factor kappa-B — a master transcription factor that controls genes for TNF-α, IL-1β, IL-6, and other pro-inflammatory cytokines; it is normally held inactive in the cytoplasm by a family of inhibitor proteins called IκBs, the master inflammatory transcription factor. The gene NFKBIE encodes IκBε (IκB-epsilon)²² IκBε (IκB-epsilon)
Inhibitor of kappa-B epsilon — a member of the IκB family that binds primarily to RELA (p65) and REL NF-κB subunits, sequestering them in the cytoplasm and preventing inflammatory gene transcription; IκBε contains six closely spaced ankyrin repeats and operates more slowly than IκBα, acting as a late-phase dampener of NF-κB oscillations, one of the key brake proteins that normally keeps NF-κB restrained. The rs2233434 variant introduces a valine-to-alanine substitution at position 55 (p.Val55Ala in current transcript nomenclature; Val194Ala in older transcript annotations), which impairs the ability of IκBε to suppress NF-κB activity. In a landmark genome-wide association study, this G-allele variant emerged as one of the most significant non-HLA RA susceptibility loci identified to date.

The Mechanism

IκBε normally binds RELA and REL NF-κB subunits in the cytoplasm through its six ankyrin repeats, preventing them from entering the nucleus and activating inflammatory gene transcription. When cells are stimulated with pro-inflammatory signals (TNF-α, LPS, or antigen receptor engagement), IKK kinases phosphorylate IκBε, targeting it for proteasomal degradation and releasing NF-κB to translocate to the nucleus. Unlike the rapidly recycled IκBα, IκBε operates on a slower timescale and is responsible for dampening the late phase of NF-κB activation — functioning as an oscillation dampener that prevents sustained chronic inflammatory signaling.

The Val55Ala substitution is located in the ankyrin repeat domain of IκBε. Functional assays by Myouzen et al.³³ Functional assays by Myouzen et al.
Myouzen et al. 2012 — transfected HEK293 cells with risk (G-T) versus non-risk (A-C) haplotype constructs and measured NF-κB activity by luciferase reporter; the risk haplotype showed higher NF-κB transactivation and lower allelic transcript abundance, consistent with reduced inhibitory capacity demonstrated that the risk haplotype carrying the G allele of rs2233434 shows higher NF-κB activity compared to the non-risk haplotype, along with slightly lower transcript abundance — together suggesting that this variant both reduces the amount of IκBε protein and impairs the inhibitory function of whatever IκBε is produced. The net result is a leaky NF-κB brake: inflammatory stimuli activate NF-κB more easily, and the inflammatory signal lingers longer before being extinguished.

The Evidence

The primary discovery came from a large GWAS and two-stage replication in the Japanese population⁴⁴ large GWAS and two-stage replication in the Japanese population
Myouzen et al. 2012, PLoS Genetics — Japanese GWAS (stage 1) plus two independent replication cohorts; 7,907 RA cases and 35,362 controls total; rs2233434 reached genome-wide significance at OR=1.20, 95% CI 1.15–1.26, p=1.3×10⁻¹⁵. This established NFKBIE as the second-largest non-HLA RA risk locus at the time of discovery.

The association has since been replicated across multiple ancestries. Trans-ethnic meta-analysis⁵⁵ Trans-ethnic meta-analysis
Identified NFKBIE as having strong cross-population support: OR_EUR=1.25, OR_EAS=1.24, OR_AA=1.50, with a combined trans-ethnic p=1.57×10⁻¹⁹; the variant was identified as approximately 400 times more likely than the neighboring rs2233433 to be the pathogenic variant at this locus, with a posterior probability of pathogenicity of 0.482 confirmed that the effect is consistent in European (OR=1.25) and African American populations (OR=1.50), with the latter showing a notably larger effect size despite the G allele being rarer in African populations (~6%). These consistent trans-ethnic effects support a genuine biological role for this variant rather than a population-specific linkage artifact.

Beyond RA, a separate line of evidence connects this variant to drug response. Hashizume et al. 2016⁶⁶ Hashizume et al. 2016
Hashizume et al., Modern Rheumatology 2016 — overexpression of Val194Ala (rs2233434) mutant NFKBIE in human RA synovial fibroblasts (MH7A) showed reduced SLC19A1 mRNA compared to wild-type NFKBIE overexpression, particularly at methotrexate concentrations above 5 μM; methotrexate-polyglutamate accumulation was also reduced showed that the Val194Ala variant reduces expression of SLC19A1, the primary membrane transporter responsible for methotrexate uptake into cells. This creates a potential double vulnerability for G-allele carriers: higher baseline inflammatory signaling driving RA development, and potentially reduced efficacy of the first-line RA treatment methotrexate.

The risk allele frequency shows marked population stratification: G is found at approximately 18% in East Asian populations compared to only 4% in Europeans and 2% in South Asians. This higher frequency in East Asia may contribute to observed differences in RA prevalence and presentation across ancestries.

Practical Actions

For G-allele carriers, the most clinically relevant implication concerns awareness of RA risk markers and proactive monitoring. RA develops in predisposed individuals when genetic susceptibility combines with environmental triggers — smoking, periodontal disease, infections, and hormonal transitions. Early joint inflammation treated before significant cartilage erosion occurs preserves function dramatically better than late intervention.

The SLC19A1 connection also has practical implications: if G-allele carriers with RA are prescribed methotrexate and show inadequate response at standard doses, the NFKBIE variant may contribute to reduced drug uptake. Awareness of this pharmacogenomic dimension can guide earlier escalation to biological therapies when needed.

Interactions

NFKBIE functions within the canonical NF-κB pathway upstream of STAT4 (rs7574865). IκBε controls whether NF-κB enters the nucleus to produce IL-12 and IL-23 — the cytokines that STAT4 senses to drive Th1 polarization. Individuals carrying the NFKBIE G allele (more NF-κB activity, more IL-12/IL-23 production) together with the STAT4 T allele (higher IL-12/IL-23 sensitivity) may have amplified Th1 polarization relevant to both RA and other autoimmune conditions. This interaction has not been formally characterized for RA, but parallels the well-studied NFKBIE × STAT4 genetic architecture in SLE.

rs2233433 is a neighboring nsSNP in NFKBIE (Pro175Leu on older transcript numbering) that was studied in haplotype context with rs2233434 in the Myouzen et al. paper; the two form a risk haplotype (G-T) where both contribute to enhanced NF-κB activity. The rs41298997 IKBKE variant is in a different gene (IKKε kinase) but shares the NF-κB signaling axis; compound risk at both loci could amplify inflammatory signaling through both the inhibitor (NFKBIE) and kinase (IKBKE) arms of the pathway.

The thyroid-stimulating hormone receptor is the central target of Graves' disease autoimmunity. Stimulating autoantibodies (TRAbs) against TSHR permanently mimic TSH, overriding the pituitary's feedback control and driving unchecked thyroid hormone production. rs2268458 is an [intronic variant | A variant within a non-coding intron that can influence gene regulation and expression without altering the protein sequence] in the unusually large intron 1 of the TSHR gene — the same region that harbours the better-studied rs12101255 and rs179247 Graves' susceptibility variants. What sets rs2268458 apart within this locus is a notable absence: unlike some TSHR SNPs, this variant shows no statistically significant association with Graves' ophthalmopathy (GO), the orbital complication affecting 25–30% of Graves' patients, suggesting that not all intron 1 variants are regulatory equivalents.

The Mechanism

TSHR intron 1 contains regulatory elements that control tissue-restricted expression of the receptor, including in thymic epithelial cells — where autoreactive T cells are educated and eliminated. Reduced intrathymic TSHR expression, caused by risk variants in this region, means fewer TSHR-presenting cells are available for clonal deletion of autoreactive T cells, allowing TSHR-reactive T cells to escape into the periphery. A landmark 2014 PNAS study by Stefan et al.¹¹ Stefan et al.
Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity established this mechanism for adjacent rs12101255/rs12101261, identifying interferon-alpha-induced PLZF repressor binding as the epigenetic link between viral infection and thyroid autoimmunity.

The precise regulatory role of rs2268458 within this intron 1 region has not been separately characterised at the mechanistic level — Yin et al. 2008²² Yin et al. 2008
Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy noted that "direct functional analyses are now needed to help explain the mechanisms of this TSHR gene susceptibility." The variant's distinct phenotypic signature — Graves' disease susceptibility without ophthalmopathy association — implies it tags a regulatory effect at the TSHR locus that diverges from the orbital-disease pathway.

The finding that CC homozygotes face elevated relapse risk after antithyroid drug treatment (Eliana 2017) suggests the C allele may maintain a pro-autoimmune state that persists even after pharmacological thyroid function control — potentially reflecting impaired re-establishment of tolerance once the autoimmune response is triggered.

The Evidence

rs2268458 was identified as the most-associated TSHR SNP in a landmark study by Dechairo et al.³³ Dechairo et al.
Association of the TSHR gene with Graves' disease: the first disease-specific locus (2005), analysing 1,059 autoimmune thyroid disease cases and 971 controls. The haplotype containing rs2268458 reached P<1×10⁻⁶ (OR 1.7) in discovery and was independently replicated: GD P=2×10⁻⁶, OR 1.3, in 1,366 cases and 1,061 UK Caucasian controls. No association was found with autoimmune hypothyroidism, establishing this as a Graves'-specific signal.

Yin et al.⁴⁴ Yin et al.
Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy (2008) replicated the association in 200 female Caucasian GD patients versus 118 controls (OR 1.8, P=0.018 for C-containing genotype), and specifically examined 120 Graves' ophthalmopathy patients: no association with GO was found. The Xiong et al. meta-analysis (4,790 GD cases, 5,350 controls)⁵⁵ Xiong et al. meta-analysis (4,790 GD cases, 5,350 controls)
Genetic associations of the thyroid stimulating hormone receptor gene with Graves diseases and Graves ophthalmopathy (2016) confirmed that rs2268458 does not distinguish GO patients from GD-without-GO, reinforcing the variant-specific null ophthalmopathy finding.

A clinical study by Eliana et al.⁶⁶ Eliana et al.
Role of CTLA-4, TSHR and regulatory T-cells as risk factors for relapse in Graves disease (2017) extended rs2268458's clinical relevance: CC homozygotes showed significantly elevated relapse rates 12 months after antithyroid drug cessation (P=0.003) in 144 Indonesian patients, suggesting the CC genotype is not only a disease-onset marker but a treatment-response predictor.

Practical Actions

The C allele elevates Graves' disease susceptibility approximately 1.3–1.8-fold. Because rs2268458 does not predict ophthalmopathy independently, risk management for C allele carriers focuses on Graves' disease itself — early detection, thyroid function surveillance, and reducing modifiable autoimmune triggers.

CC homozygotes face the double burden of elevated disease onset risk and, if Graves' disease develops, elevated relapse risk after antithyroid drug treatment — making upfront awareness of treatment options (radioiodine ablation or thyroidectomy as definitive therapy) particularly relevant when discussing treatment strategy with an endocrinologist.

Selenium at 100–200 mcg/day has RCT evidence for reducing TRAb titres and autoimmune thyroid activity in Graves' patients; because the TSHR intron 1 risk variants appear to lower the immune-tolerance threshold for TSHR, selenium's immunomodulatory effect is a genotype-informed intervention for C allele carriers.

Interactions

rs2268458 maps to TSHR intron 1 alongside rs12101255 (the most-studied Graves' intron 1 SNP, with OR ~1.5–2.2 in meta-analyses) and rs179247. These three variants are in linkage disequilibrium and were co-studied in early TSHR haplotype work; whether rs2268458 contributes independently or purely as a tag for the rs12101255 haplotype block has not been resolved.

Syed et al. 2007⁷⁷ Syed et al. 2007
Preliminary evidence for interaction of PTPN12 polymorphism with TSHR genotype and association with Graves' ophthalmopathy demonstrated statistical interaction between PTPN12 polymorphisms and the TSHR rs2268458 genotype in mild-to-moderate Graves' ophthalmopathy — an intriguing finding given that rs2268458 alone shows no GO association, suggesting the ophthalmopathy signal may emerge only in combination with PTPN12 variants rather than from rs2268458 in isolation.

Beyond the TSHR locus, independent Graves' susceptibility loci include PTPN22 rs2476601 (T-cell activation threshold), CTLA4 rs3087243 and rs231775 (T-cell checkpoint control), and HLA-DRB1 alleles (antigen presentation) — each acting through mechanisms distinct from the thymic TSHR expression pathway.

One of the most intriguing PCOS susceptibility loci is not a single gene but a functional cluster on chromosome 12q13.2, where three seemingly distinct biological processes converge: EGF receptor signalling, vesicular membrane trafficking, and androgen transcriptional regulation. The rs2271194 variant is an intronic/splice-region tag SNP within ERBB3/HER3¹¹ ERBB3/HER3
Erb-b2 receptor tyrosine kinase 3; a member of the epidermal growth factor receptor family that forms obligate heterodimers with ERBB2 to amplify growth factor signalling and, uniquely among the ErbB family, lacks intrinsic kinase activity, on a haplotype that has been associated with PCOS in large European cohorts and that contains RAB5B²² RAB5B
Ras-related protein Rab-5B; a small GTPase regulating early endosomal biogenesis and receptor internalisation and recycling after ligand binding and PA2G4 as co-located candidates.

The Mechanism

The functional picture at 12q13.2 is multifactorial, involving at least three interacting mechanisms identified through exome sequencing of PCOS theca cells and single-cell RNA sequencing:

Vesicular trafficking (RAB5B): In normal theca cells, stimulation with forskolin (a proxy for LH/cAMP signalling) upregulates RAB5B — the early endosomal GTPase that controls receptor recycling and downstream signalling duration. Harris et al. 2025³³ Harris et al. 2025
Multimodal integration of genomic data at the PCOS-associated 12q13.2 locus. Int J Mol Sci 26 showed that this upregulation is specifically impaired in PCOS theca cells, reducing the cells' ability to correctly internalise and recycle signalling receptors — including the insulin receptor and ERBB family members — after ligand activation. A complementary paper found that the enhancer variant rs1081975 at this locus shows perfect colocalization with RPS26/RAB5B/SUOX eQTLs (posterior probability 1.0), confirming RAB5B expression is directly regulated from this haplotype.

Androgen co-repression (PA2G4/ERBB3 interaction): The locus also encodes PA2G4 (ErbB3 binding protein 1), a transcriptional co-repressor of the androgen receptor. Harris et al. 2023⁴⁴ Harris et al. 2023
Loci on chromosome 12q13.2 encompassing ERBB3, PA2G4 and RAB5B are associated with PCOS. Gene 853:147059 demonstrated that PA2G4 interacts physically with the ERBB3 cytoplasmic domain, and that a PA2G4 promoter SNV in the associated haplotype drives markedly reduced PA2G4 expression in PCOS theca cells (padj = 3.82×10⁻³⁰ after forskolin). Because PA2G4 is a corepressor of androgen receptor activity, its reduction releases androgen receptor signalling from normal suppression, contributing to the excess androgen production that defines PCOS.

ERBB3 expression: In normal theca cells, ERBB3 is downregulated by cAMP/forskolin stimulation. The 12q13.2 haplotype appears to alter this regulatory response, contributing to aberrant EGF receptor activity in PCOS cells.

The Evidence

The chromosome 12q13.2 locus was first identified in a Han Chinese GWAS: Shi et al. 2012⁵⁵ Shi et al. 2012
Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet 44:1020–1025 analysed 8,226 PCOS cases and 7,578 controls, identifying 12q13.2 among eight newly significant loci, with candidate genes enriched for insulin signalling, sexual hormone function, and type 2 diabetes pathways. The rs2271194-A allele specifically reached genome-wide significance in the largest European PCOS GWAS: Day et al. 2018⁶⁶ Day et al. 2018
Large-scale GWAS meta-analysis of PCOS suggests shared genetic architecture. PLoS Genet 14:e1007813 meta-analysed 10,074 PCOS cases and 103,164 European controls, confirming rs2271194-A (beta 0.0971, SE 0.0166, p=5×10⁻⁹) among replicated PCOS loci. Mendelian randomization in the same dataset demonstrated causal associations with higher insulin resistance (P=6×10⁻⁴) and lower SHBG — a finding directly relevant to the 12q13.2 locus's enrichment for insulin signalling candidates.

The protein-level relevance of ERBB3 was confirmed by colocalization analysis: Censin et al. 2021⁷⁷ Censin et al. 2021
Colocalization analysis of PCOS to identify potential disease-mediating genes and proteins. Eur J Hum Genet 29:1096–1104 found that ERBB3 protein QTLs co-localize with PCOS genetic signals with posterior probability consistent with a shared causal variant, placing ERBB3 among seven proteins explaining roughly 30% of known PCOS signals.

Notably, a 2025 cross-trait analysis found that ERBB3 also emerges as a central shared gene between PCOS and asthma, both of which show inflammatory and hormonal dysregulation involving EGF receptor pathways — suggesting the 12q13.2 locus may have broader pleiotropic effects beyond reproductive phenotypes.

Practical Actions

The 12q13.2 locus is specifically enriched for insulin signalling pathways, making metabolic monitoring and insulin-sensitising interventions especially relevant for women carrying the risk A allele. Unlike the purely reproductive DENND1A locus, this locus connects directly to insulin resistance, making it a metabolic-reproductive PCOS subtype. Myo-inositol acts as a second messenger in the insulin/FSH signalling cascade and has specific evidence for improving ovarian insulin sensitivity in PCOS. Spearmint tea has documented anti-androgenic activity via LH/FSH modulation. Monitoring free testosterone and HOMA-IR (insulin resistance index) captures both arms of this locus's biology.

Interactions

ERBB3 is one of three EGF receptor family members (alongside ERBB2 and ERBB4) with PCOS associations. The rs2271194 (ERBB3) and rs2178575 (ERBB4) loci mark distinct chromosomal regions and likely contribute independently to PCOS risk. Combined risk allele burden across ERBB family loci may amplify follicular signalling deficits, though published compound effect sizes do not exist for this combination. The RAB5B impairment in vesicular trafficking may also amplify insulin receptor dysregulation in women co-carrying rs7852296 (DENND1A) risk alleles, as both pathways converge on receptor internalisation and recycling in theca cells.

The TMPRSS6 gene produces matriptase-2¹¹ matriptase-2
A type II transmembrane serine protease expressed primarily in liver cells that acts as the body's main brake on hepcidin production, the enzyme that keeps hepcidin — the master iron-regulatory hormone — in check. Most genetic research on TMPRSS6 has focused on the Ala736Val variant (rs855791), which sits in the enzyme's catalytic domain. But rs228921, located roughly 2 kilobases upstream of the TMPRSS6 transcription start site, tags a second, independent signal at this locus. This upstream variant operates through a different mechanism: instead of altering the enzyme's activity, it likely affects how much matriptase-2 protein the liver produces. The result, however, is similar — lower matriptase-2 output means less hepcidin suppression, higher hepcidin, and reduced iron absorption from the gut.

The Mechanism

Matriptase-2 normally cleaves hemojuvelin²² hemojuvelin
A membrane-bound co-receptor that activates the BMP/SMAD signaling cascade, which drives hepcidin gene transcription in hepatocytes from the surface of liver cells. By removing this coreceptor, matriptase-2 blocks the BMP/SMAD pathway³³ BMP/SMAD pathway
Bone morphogenetic protein / son of mothers against decapentaplegic — a signaling cascade that upregulates hepcidin transcription and reduces hepcidin secretion. When matriptase-2 is produced at lower levels — as may occur with the G allele at rs228921 — this suppression is less effective. Hepcidin levels rise, ferroportin on gut enterocytes is internalized and degraded, and less dietary iron crosses the gut wall into the bloodstream.

rs228921 sits in low linkage disequilibrium with rs855791 (r² < 0.1 in European and Indian Asian populations), confirming that it is an independent genetic signal rather than a proxy for the Ala736Val variant. This means the two variants can be studied and act together as additive genetic risk⁴⁴ additive genetic risk
When two independent variants at the same locus both predispose to lower iron status, carrying both can compound the effect. An individual who is GG at rs228921 and also AA at rs855791 carries risk at two independent locations in the TMPRSS6 gene.

The Evidence

The landmark genome-wide association study by Chambers et al.⁵⁵ Chambers et al.
Chambers JC et al. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet, 2009 — conducted in 16,001 individuals of European and Indian Asian ancestry — identified rs228921 as independently associated with hemoglobin levels at genome-wide significance (combined P = 1.9 × 10⁻¹⁰). The variant clustered with rs228918 and rs228919 in a separate haplotype block from the primary rs855791/rs4820268 cluster, confirming its independent contribution to iron phenotype variation.

A systematic review⁶⁶ systematic review
Gichohi-Wainaina WN et al. Inter-ethnic differences in genetic variants within the transmembrane protease, serine 6 (TMPRSS6) gene associated with iron status indicators. Genes Nutr, 2015 documented comparable minor allele frequencies for rs228921 across Caucasian (MAF ~0.41) and Indian Asian (MAF ~0.48) populations, with this variant included among the eight TMPRSS6 SNPs showing inter-ethnic differences in association with iron status indicators.

A study in female Black South African populations found that the rs228918/rs228921 GG haplotype was associated with lower odds of elevated soluble transferrin receptor (sTfR > 8.3 mg/L; OR: 0.79, 95% CI: 0.63–0.98), illustrating how the biological effect of this upstream variant depends on haplotype context and may differ across ancestries — a reminder that iron-related genetic associations are influenced by population-specific haplotype backgrounds.

Practical Actions

For carriers of one or two G alleles, the implications parallel those of rs855791 but are additive: reduced TMPRSS6 activity → elevated hepcidin → lower iron absorption efficiency. The practical response focuses on the same strategies that improve iron uptake in the face of high hepcidin: pairing non-heme iron sources with vitamin C, choosing heme iron when possible, avoiding absorption inhibitors at iron-containing meals, and monitoring iron stores with periodic ferritin and transferrin saturation testing.

If a supplement is needed, iron bisglycinate⁷⁷ iron bisglycinate
A chelated amino acid form of iron that is absorbed partly through peptide transporters (PEPT1), bypassing the ferroportin bottleneck that hepcidin controls. Also labeled chelated iron or gentle iron is preferable to ferrous sulfate because its absorption is less dependent on ferroportin. Every-other-day dosing maximizes fractional absorption by allowing hepcidin to reset between doses.

The combined genetic picture matters: if you also carry the risk allele at rs855791 (or rs4820268), the two independent TMPRSS6 signals compound your predisposition toward lower iron absorption, making monitoring more important.

Interactions

rs228921 and rs855791 are in low LD (r² < 0.1) and represent independent signals at the TMPRSS6 locus — they can co-occur in the same individual and their effects are additive. Carrying both risk alleles compounds the predisposition to lower iron status. rs228918, rs228919, and rs575620 form a tight haplotype cluster with rs228921 and are likely in near-complete LD with each other.

TMPRSS6 variants also interact with HFE variants⁸⁸ HFE variants
HFE encodes a protein involved in hepcidin signaling. Loss-of-function variants C282Y (rs1800562) and H63D (rs1799945) reduce hepcidin and cause iron overload in homozygotes. See rs1800562. In individuals with HFE hemochromatosis variants, a hepcidin-reducing TMPRSS6 variant would amplify iron loading; conversely, in HFE carriers the higher hepcidin from TMPRSS6 risk alleles partially offsets the HFE-driven reduction. These opposing effects mean the clinical interpretation depends on what HFE variants are co-present.

The rs2546890 variant sits approximately 2,000 base pairs upstream of the IL12B gene¹¹ IL12B gene
located at chromosome 5q33.3, encodes the p40 subunit shared by interleukin-12 and interleukin-23, within a non-coding RNA locus designated LOC285626. IL-12 and IL-23 are cytokines produced by dendritic cells and macrophages that act as master switches for adaptive immune responses: IL-12 drives naive T cells toward the Th1 (IFN-γ-producing) lineage, while IL-23 sustains the Th17 (IL-17-producing) lineage. Both arms are implicated in autoimmune demyelination, psoriatic inflammation, and immune-mediated liver disease. The rs2546890 A allele has been associated in large genome-wide studies with elevated risk of multiple sclerosis, psoriasis, and primary biliary cholangitis — three immunologically distinct diseases unified by shared IL-12/IL-23 pathway dysregulation.

The Mechanism

rs2546890 is annotated as a non-coding transcript variant in the LOC285626 locus. Its position in the IL12B upstream regulatory region places it within a genomic neighborhood that contains multiple independently replicated autoimmune susceptibility signals. The IL12B locus at 5q33.3 harbors several GWAS-identified variants (including rs6887695 in the upstream region and rs3212227 in the 3′ UTR) that form a risk haplotype functionally linked to elevated p40 subunit expression in monocytes and dendritic cells. Carriers of the IL12B risk haplotype show increased IL12B mRNA and protein in antigen-presenting cells, leading to higher serum IL-12 and a Th1-polarized immune milieu²² increased IL12B mRNA and protein in antigen-presenting cells, leading to higher serum IL-12 and a Th1-polarized immune milieu
The p40 subunit is shared by both IL-12 and IL-23 heterodimers, so expression changes affect both cytokine outputs simultaneously. rs2546890 is in linkage disequilibrium with variants in this regulatory haplotype, likely tagging the same functional effect — enhanced transcription factor access to the IL12B promoter region during innate immune activation.

The Evidence

The association of rs2546890 with multiple sclerosis has been established across multiple large GWAS cohorts. The 2011 International MS Genetics Consortium (IMSGC) study³³ 2011 International MS Genetics Consortium (IMSGC) study
Sawcer et al., Nature 2011, PMID 21833088 analysed 9,772 MS cases and 16,849 controls of European ancestry across 23 research groups and identified the IL12B locus region among at least 29 novel susceptibility signals. The 2019 IMSGC genomic map⁴⁴ 2019 IMSGC genomic map
International MS Genetics Consortium, Science 2019, PMID 31604244 expanded this to 47,429 MS cases and 68,374 controls, confirming rs2546890 among 200 autosomal susceptibility variants, with an odds ratio of approximately 1.11 (p = 1×10⁻¹¹). An independent Italian cohort study Leone et al., PLOS ONE 2013, PMID 23785401⁵⁵ Leone et al., PLOS ONE 2013, PMID 23785401 found that rs2546890 near IL12B was the only non-HLA variant significantly associated with cerebrospinal fluid oligoclonal bands — a biomarker of CNS-compartmentalised inflammation — in 1,115 Italian MS patients (OR 1.45, 95% CI 1.09–1.92), validated by in silico replication in Scandinavian and Belgian cohorts.

For psoriasis, the IL12B locus is one of the most robustly replicated susceptibility signals. GWAS Catalog records for rs2546890 show associations at p = 1×10⁻²⁰ (OR 1.54, 95% CI 1.32–1.79) and p = 3×10⁻³⁵ (OR 1.39, 95% CI 1.32–1.47) across separate European cohorts. Pharmacogenomic studies link rs2546890 to biologic treatment response: Ovejero-Benito et al., Pharmacogenomics 2017, PMID 28470127⁶⁶ Ovejero-Benito et al., Pharmacogenomics 2017, PMID 28470127 found association with etanercept response at 6 months (n=68), and the same group Pharmacogenomics 2018, PMID 29192552⁷⁷ Pharmacogenomics 2018, PMID 29192552 found that rs2546890 was among five SNPs associated with PASI75 response to adalimumab or infliximab at 3 months (n=95). For primary biliary cholangitis, an international GWAS meta-analysis Cordell et al., 2015, PMID 26394269⁸⁸ Cordell et al., 2015, PMID 26394269 identified the locus at p = 5×10⁻¹² (beta = 0.133). The convergence of three immunologically distinct conditions on the same variant underscores its role as a broad immune-regulatory signal rather than a disease-specific variant.

Practical Actions

For individuals carrying one or two A alleles, the primary actionable implications are: (1) heightened monitoring for early signs of MS, psoriasis, and autoimmune liver disease; (2) awareness of the pharmacogenomic relevance to IL-12/IL-23 pathway-targeting biologics. Ustekinumab (Stelara) targets the p40 subunit encoded by IL12B — the protein whose expression is amplified by the risk haplotype this variant tags. Pharmacogenomic studies show that IL12B genotype influences ustekinumab response in psoriasis, making this result clinically relevant for biologic selection. Similarly, IL-12/IL-23 pathway-blocking biologics used in MS (natalizumab does not target this pathway directly, but newer agents such as ofatumumab act upstream in the B-cell/innate immune cascade implicated by this locus) are of increasing relevance.

Interactions

rs2546890 acts within the broader IL12B susceptibility haplotype that includes rs6887695 (upstream) and rs3212227 (3′ UTR). Individuals carrying risk alleles at rs2546890 alongside the IL12B 3′ UTR risk haplotype (rs3212227) likely have compounding effects on p40 expression. The IL23R rs11209026 (R381Q) loss-of-function variant provides strong protection against MS, psoriasis, IBD, and ankylosing spondylitis by reducing IL-23 receptor signaling downstream of the p40-containing IL-23 heterodimer. Carrying both the rs2546890 A risk allele (elevated IL12B expression) and the IL23R rs11209026 protective A allele creates a partial antagonistic interaction that would benefit from compound action analysis. The existing IL12B SNP rs12188300 in GeneOps operates on a partially overlapping locus; individuals carrying risk alleles at both rs12188300 and rs2546890 likely have additive effects on IL-12/IL-23 pathway amplification.

CD14 is the first responder to bacterial invasion. Expressed on the surface of monocytes and macrophages¹¹ monocytes and macrophages
the frontline phagocytic cells of innate immunity, CD14 acts as a co-receptor that binds lipopolysaccharide (LPS) — the potent endotoxin coating the outer membrane of every gram-negative bacterium in your gut, on your skin, and in the environment. Once CD14 captures LPS, it hands it off to TLR4/MD-2²² TLR4/MD-2
Toll-like receptor 4, the signal-transducing partner that fires the NF-κB inflammatory cascade, triggering cytokine release and the full inflammatory response to bacterial threats.

The -159C>T promoter variant (rs2569190, also reported as -260C>T depending on the transcription start site used) is one of the most studied functional SNPs in immunogenetics. It sits in a GC-box element in the CD14 promoter³³ GC-box element in the CD14 promoter
a transcription factor binding site ~159 base pairs upstream of the coding sequence and changes how much CD14 protein your immune cells produce. The variant is notable for driving one of the clearest gene-environment interactions in all of allergy research.

The Mechanism

The T allele (reported as A on the plus strand in genome files; the gene is on the minus strand of chromosome 5) is associated with a functional impact on CD14 transcription⁴⁴ functional impact on CD14 transcription
In vivo chromatin immunoprecipitation shows twice as much RNA polymerase II recruited to the T-allele haplotype, indicating stronger transcription initiation, though allele-specific transcript quantification finds similar mRNA output between haplotypes. The net result is that TT homozygotes have significantly higher circulating soluble CD14 (sCD14)⁵⁵ TT homozygotes have significantly higher circulating soluble CD14 (sCD14)
sCD14 is shed from monocyte surfaces and acts as a soluble pattern-recognition molecule extending LPS detection to cells that don't express membrane CD14. CC homozygotes produce less sCD14 and have a more muted basal response to bacterial endotoxin.

This expression difference creates the paradox at the heart of the hygiene hypothesis: higher CD14 = more efficient LPS detection = stronger Th1 skewing = protection against allergic sensitization — but only when microbial exposure is high enough to exploit that capacity. In environments with low endotoxin load (urban living, formula feeding, no farm exposure), the T allele's higher CD14 expression may paradoxically drive heightened allergic responses by amplifying immune reactivity without the Th1-steering effect that requires persistent bacterial stimulation.

The Evidence

Baldini et al. 1999⁶⁶ Baldini et al. 1999
Original discovery in 481 children: TT homozygotes had significantly higher sCD14 and lower total IgE among skin-test-positive children (p=0.004) established that the T allele of CD14/-159 is the higher-expression variant and reduces IgE-mediated sensitization — but only in atopic children, implying a gene-environment gate.

The gene-environment interaction was definitively demonstrated by Simpson A et al. 2006⁷⁷ Simpson A et al. 2006
Study of 442 Manchester children showing opposite CD14 allele effects depending on farming exposure. In children with low endotoxin exposure, the C allele (GG genotype on plus strand) was the allergy risk genotype. In children with high endotoxin exposure (farm families), the T allele (AA on plus strand) became the risk genotype. The crossover was replicated across four independent populations (rural Europe, Manchester, Detroit, Barbados), with the most dramatic crossover effects seen in the high-contrast exposure settings.

A meta-analysis of 23 studies including 4,780 cases and 5,650 controls⁸⁸ A meta-analysis of 23 studies including 4,780 cases and 5,650 controls
BMC Medical Genetics 2011, PMID 21745379 found that when restricted to homogeneous atopic asthma phenotypes, the T allele is protective: TT vs CC OR = 0.67 (95% CI 0.54-0.84) and CT vs CC OR = 0.80 (95% CI 0.66-0.95), consistent with a codominant protective effect — in populations without stratification by endotoxin exposure.

Kerkhof et al. 2012⁹⁹ Kerkhof et al. 2012
JACI, PMID 21996339 pooled three allergy-prevention intervention cohorts and showed the genotype determines whether reducing microbial exposure in infancy helps or harms: interventions that decreased indoor allergen/endotoxin exposure were protective in CC children but increased atopy in TT children — a striking pharmacogenomic-style genotype-determines- direction effect.

For infectious disease, the T allele (AA genotype) consistently shows survival advantage. Mansur et al. 2015¹⁰¹⁰ Mansur et al. 2015
Prospective cohort of 417 sepsis patients, PMID 26020644 found that C-allele carriers had 23% 30-day mortality vs 13% for TT homozygotes, with the C allele remaining a significant independent covariate in multivariate Cox regression (HR 2.11, 95% CI 1.08-4.12, p=0.028). Higher sCD14 from the T allele appears to improve LPS clearance and dampen the cytokine storm cascade driving organ failure.

Conversely, for SARS-CoV-2, Pati et al. 2021¹¹¹¹ Pati et al. 2021
JID, PMID 33822099 found the T allele (higher CD14 expression) correlates with higher COVID-19 infection rates and mortality across European countries (r=0.57 and r=0.61 respectively), while the CC genotype was protective against severe SARS. This is consistent with the hygiene-hypothesis model: high CD14 may amplify inflammatory responses to novel viral-associated LPS signals or drive excessive innate immune activation.

Practical Actions

The actionable takeaway from this literature is not "which allele is good" — both have context-dependent advantages — but rather understanding how your genotype interacts with your microbial environment. GG (CC in papers) carriers benefit most from increasing microbial diversity; their lower-expression CD14 means they need richer bacterial stimulation to drive appropriate Th1 immune development and LPS tolerance. AA (TT) carriers already produce abundant CD14 and may be more sensitive to both high endotoxin environments and novel inflammatory triggers. For sepsis prevention, AA carriers appear inherently more resilient. For allergy prevention in low-endotoxin environments, GG carriers are at higher baseline risk and benefit most from microbial exposure strategies.

Probiotic strain selection matters for this SNP. Gram-negative probiotics and fermented foods containing LPS-like molecules (e.g. Bifidobacterium species, spore-forming Firmicutes) stimulate the CD14/TLR4 axis differently than gram-positive species with lipoteichoic acid. For GG carriers building Th1 tolerance, gram-negative-rich fermented foods provide endotoxin-tolerizing stimulation without excessive inflammatory drive.

Interactions

The most important interaction is with TLR4 (rs4986790, Asp299Gly)¹²¹² TLR4 (rs4986790, Asp299Gly)
TLR4 is the downstream signal transducer for LPS delivered by CD14. CD14 captures LPS and hands it to TLR4; variants in both genes affect the same LPS-sensing pathway and may have compounded effects. Individuals with low-CD14 expression (GG at rs2569190) combined with blunted TLR4 signaling (Asp299Gly at rs4986790) would have doubly impaired LPS recognition.

IL-1β (rs16944)¹³¹³ IL-1β (rs16944)
a downstream cytokine produced after TLR4 activation and [TNF-α (rs1800629) | another key effector cytokine in the LPS response] polymorphisms modify the magnitude of the downstream inflammatory response once CD14-mediated LPS recognition occurs. Combined low-CD14 (GG) with high-TNF (rs1800629 AA) may create discordant signaling — poor initial sensing but exaggerated response once threshold is crossed.

For the allergy interaction: the hygiene hypothesis gene-environment effect is most pronounced for TLR2 and TLR4 co-variants. Studies suggest that the farming protective effect on allergy operates through the CD14-TLR4-IL-12 axis, and variants in any of these genes modulate how robustly farm environments suppress IgE responses.

The glucocorticoid receptor, encoded by NR3C1 on chromosome 5, is the molecular sensor for cortisol — the body's primary stress hormone. When cortisol rises (in response to physical or psychological stress, illness, or metabolic disruption), it enters cells and binds to the glucocorticoid receptor, triggering a cascade of genomic effects that regulate inflammation, metabolism, blood pressure, and — critically — the hypothalamic-pituitary-adrenal (HPA) axis itself. This rs258750 variant, an intronic single nucleotide polymorphism at position c.2181+244 of the NR3C1 gene, tags a haplotype block that spans several well-studied NR3C1 functional variants including the 9beta polymorphism (rs6198) that alters GR-beta isoform production¹¹ including the 9beta polymorphism (rs6198) that alters GR-beta isoform production
The 9beta variant disrupts a 3' UTR sequence element that destabilizes mRNA, increasing the inactive GR-beta isoform. Carriers of the G allele at rs258750 appear in haplotype studies to tag reduced glucocorticoid receptor sensitivity, with measurable downstream effects on cortisol output, metabolic parameters, and stress physiology.

The Mechanism

The glucocorticoid receptor exists in two primary isoforms: GR-alpha, which is transcriptionally active and mediates cortisol's genomic effects, and GR-beta, an alternatively spliced isoform that acts as a dominant-negative inhibitor²² dominant-negative inhibitor
GR-beta forms dimers with GR-alpha, impairing its ability to bind glucocorticoid response elements of GR-alpha signaling. The rs258750 G allele tags a haplotype in the 3' region of NR3C1 that has been associated with increased GR-beta production relative to GR-alpha, thereby reducing the net glucocorticoid signaling response to circulating cortisol. The intronic position of rs258750 itself suggests it may influence splice site efficiency or regulatory element function within the complex multi-transcript NR3C1 locus.

For the reproductive axis, the consequences of altered glucocorticoid sensitivity are significant. Cortisol acts on hypothalamic neurons that control GnRH pulsatility³³ GnRH pulsatility
Gonadotropin-releasing hormone — the master pulse generator that drives LH and FSH release from the pituitary. Elevated cortisol directly suppresses GnRH pulse frequency and amplitude, reducing downstream LH and FSH secretion. In women with functional hypothalamic amenorrhea — a stress-induced cessation of ovulation — increased basal cortisol and blunted CRH responsiveness are hallmarks⁴⁴ In women with functional hypothalamic amenorrhea — a stress-induced cessation of ovulation — increased basal cortisol and blunted CRH responsiveness are hallmarks
Morrison et al. 2021 review of FHA pathophysiology. Reduced glucocorticoid receptor sensitivity in G allele carriers may partially buffer this HPA-to-HPG suppressive pathway, but it also alters the HPA axis's negative feedback dynamics, with complex consequences for both cortisol homeostasis and reproductive timing.

The Evidence

The NR3C1 9beta haplotype — which rs258750 appears to tag — has been studied across multiple phenotypes. Chung et al. 2009 studied GENOA families across three ethnic groups⁵⁵ Chung et al. 2009 studied GENOA families across three ethnic groups
Chung CC et al. J Clin Endocrinol Metab 2009 and found the 9beta variant in the NR3C1 3' UTR associated with multiple blood pressure measures in European-Americans, proposing that increased GR-beta production reduces net glucocorticoid receptor signaling and blood pressure regulation.

Metabolically, Trementino et al. 2012 studied 61 Cushing's syndrome patients⁶⁶ Trementino et al. 2012 studied 61 Cushing's syndrome patients
Trementino L et al. Eur J Endocrinol 2012 — people with chronically elevated cortisol — and found carriers of the 9beta haplotype were dramatically protected from developing type 2 diabetes (19% vs 68% prevalence, P=0.001). The proposed mechanism: reduced GR sensitivity attenuates cortisol's diabetogenic effects on glucose metabolism and insulin resistance. Similarly, Rodrigues et al. 2017 followed 131 adolescents for 5 years⁷⁷ Rodrigues et al. 2017 followed 131 adolescents for 5 years
Rodrigues DM et al. Appetite 2017 and found G allele carriers consumed less sugar, had lower insulin levels, better insulin sensitivity, and lower anxiety scores.

For cortisol output itself, Nordkap et al. 2022 studied 696 Danish men⁸⁸ Nordkap et al. 2022 studied 696 Danish men
Nordkap L et al. Psychoneuroendocrinology 2022 and found the 9beta minor allele (G allele) inversely correlated with hair cortisol concentration — a measure of long-term cortisol exposure — suggesting G allele carriers have dampened HPA axis output, possibly through impaired negative feedback. Castro-Vale et al. 2021⁹⁹ Castro-Vale et al. 2021
Castro-Vale I et al. J Psychiatr Res 2021 found the 9beta risk allele significantly associated with lifetime PTSD in male war veterans, with carriers having lower hair cortisol — consistent with HPA axis blunting that impairs adaptive stress responses.

Practical Implications

The G allele at rs258750 identifies a glucocorticoid receptor haplotype with demonstrably reduced cortisol sensitivity. For reproductive function, this creates competing effects: reduced HPA suppression of GnRH under moderate stress (potentially protective) versus altered cortisol feedback dynamics that may prolong stress responses. For women with G allele genotypes who experience stress-related cycle irregularities or subfertility, the NR3C1 background suggests the HPA-HPG interface is under altered glucocorticoid control, warranting evaluation of cortisol patterns alongside standard reproductive hormones.

For men, NR3C1 expression in peritubular cells, Leydig cells, and spermatogonia¹⁰¹⁰ NR3C1 expression in peritubular cells, Leydig cells, and spermatogonia
Nordkap et al. 2017 confirmed glucocorticoid receptor protein in multiple testicular cell types indicates that glucocorticoid signaling directly modulates testicular function. Altered GR sensitivity from NR3C1 haplotype variants may contribute to the documented link between psychological stress and impaired semen quality.

Interactions

rs6198 (NR3C1 9beta): The functionally characterized 3' UTR variant (rs6198) is the primary mechanistic variant in the haplotype block that rs258750 appears to tag. Studies using rs6198 as the direct genotype provide the mechanistic foundation for this intronic variant's associations. The rs258750 G allele is likely in partial LD with the rs6198 G allele.

rs41423247 (BclI): The BclI polymorphism is the most studied NR3C1 variant for reproductive outcomes. Nordkap et al. 2017¹¹¹¹ Nordkap et al. 2017
Nordkap L et al. Andrology 2017 found BclI heterozygotes had superior semen parameters (sperm motility, inhibin B, lower FSH) in an over-dominant pattern. The rs258750 variant and BclI are in the same NR3C1 gene and may form compound haplotypes with additive or epistatic effects on overall glucocorticoid sensitivity.

Von Willebrand factor (VWF) is a molecular intermediary between damaged vessel walls and circulating platelets. When an endothelial surface tears, collagen fibres in the extracellular matrix are exposed. VWF must grip that collagen through its A3 domain¹¹ A3 domain
The A3 domain occupies residues 1686-1874 of mature VWF; it folds into a classical von Willebrand A barrel structure that positions a surface groove to engage fibrillar collagen types I and III before platelets can be recruited to seal the wound. The W1745C variant — a tryptophan-to-cysteine substitution at position 1745 — sits within this collagen-binding groove and dismantles exactly that one function without visibly disturbing anything else.

The consequence is a bleeding disorder that routine haematology labs routinely miss. VWF antigen levels are normal. The most widely used functional test — the ristocetin cofactor assay (VWF:RCo), which measures platelet-binding — is normal. Multimers are normal. Only a dedicated VWF collagen-binding assay (VWF:CB)²² VWF collagen-binding assay (VWF:CB)
Measures how well VWF adheres to immobilised type I or III collagen; the single most sensitive assay for detecting isolated A3-domain defects reveals the defect. This condition is classified as von Willebrand disease type 2M³³ von Willebrand disease type 2M
The "M" stands for multimer-independent — the bleeding defect does not arise from loss of high-molecular-weight multimers but from a qualitative functional impairment of platelet adhesion, also designated type 2CB (collagen-binding subtype). Carriers can bleed significantly from dental extractions, surgery, and childbirth while appearing fully normal on pre-operative screening panels.

The Mechanism

The VWF A3 domain adopts a von Willebrand A fold⁴⁴ von Willebrand A fold
A barrel-like beta-sheet common to VWF domains, integrins, and complement proteins; the convex face presents the collagen-binding groove with critical hydrophobic and polar contacts that presents a curved surface groove for collagen engagement. Tryptophan 1745 provides a bulky aromatic side chain that makes hydrophobic and geometric contacts within the collagen-binding interface. Substituting cysteine — a much smaller, flexible, sulphydryl- bearing residue — eliminates those contacts and likely introduces a free thiol that could form aberrant disulphide bonds, destabilising the local groove architecture without disrupting the overall protein fold, multimerisation, or Factor VIII binding capacity.

Recombinant W1745C VWF expressed in HEK293T cells by Riddell et al. showed a pronounced collagen-binding defect to both type I and type III collagen⁵⁵ Riddell et al. showed a pronounced collagen-binding defect to both type I and type III collagen
Riddell AF et al., Blood 2009; mutations were reproduced by site-directed mutagenesis and characterised in vitro; VWF:CB was severely reduced while multimer analysis was indistinguishable from wild-type, while VWF multimer patterns were indistinguishable from wild-type. Among the three A3-domain mutations characterised in that study, W1745C and S1783A both caused pronounced binding defects to both collagen types, whereas S1731T primarily affected type I collagen — demonstrating that distinct residues in the A3 groove mediate binding to the two collagen subtypes.

The Evidence

The primary characterisation is Riddell et al., Blood 2009⁶⁶ Riddell et al., Blood 2009
Riddell AF, Gomez K, Millar CM, Mellars G, Gill S, Brown SA, Sutherland M, Laffan MA, McKinnon TAJ. Blood. 2009 Oct 15;114(16):3489-96 — three families investigated; W1745C identified in one individual in compound heterozygosity with R760H; site-directed mutagenesis confirmed A3-domain collagen-binding loss with normal multimers. The individual carrying W1745C had compound heterozygosity (W1745C on one allele, R760H on the other) and showed a VWF:CB/VWF:Ag ratio of 0.3 — severely reduced, consistent with a dominant collagen-binding defect — alongside a normal multimer pattern and normal VWF:RCo. The authors proposed that isolated collagen-binding defects should be classified as a distinct VWD subtype, laying the clinical-diagnostic framework that would eventually produce the type 2M/2CB designation.

ClinVar variation 100421⁷⁷ ClinVar variation 100421
ClinGen Von Willebrand Disease Variant Curation Expert Panel classification; last evaluated August 13, 2024; four-star review status; criteria PS3, PP4, PM2_Supporting, PP3 applied classifies W1745C as Likely Pathogenic for VWD type 2M following expert panel review in August 2024. The evidence supporting classification includes the in vitro collagen-binding data, the clinical observation of decreased VWF:CB/VWF:Ag ratio in the index patient, and supporting computational evidence (PP3). The variant is entirely absent from gnomAD population databases (one allele observed in 805,812 in gnomAD exomes — effectively zero population frequency), consistent with strong negative selection.

The importance of including VWF:CB in the diagnostic workup for any bleeding history is established by Favaloro and Mohammed, 2014⁸⁸ Favaloro and Mohammed, 2014
Favaloro EJ, Mohammed S. Thromb Res 135(6):1307-16, 2014 — comparative evaluation of VWF assay platforms; VWF:CB was most discrepant from VWF:RCo precisely in type 2M/2CB patients, confirming its essential role in detecting A3-domain collagen-binding defects. Without a specific collagen-binding assay, this mutation class is systematically undetectable by standard VWD laboratory panels.

Practical Actions

For any carrier, the immediate priority is to make a concealed diagnosis visible: the VWF:CB assay must be explicitly requested. Once the defect is documented, the key clinical decision involves haemostatic coverage for procedures. DDAVP (desmopressin) — the first-line agent for type 1 and many type 2 VWD variants — releases endogenous VWF stores from endothelial Weibel-Palade bodies, but the released VWF carries the W1745C mutation and is expected to bind collagen poorly. VWF concentrate (Humate-P, Wilate, or recombinant VWF such as Vonvendi) provides functionally normal collagen-binding VWF and is the appropriate haemostatic cover when a carrier needs a procedure.

Interactions

W1745C was co-identified alongside S1783A at rs267607353⁹⁹ S1783A at rs267607353
The companion A3-domain variant from the same 2009 characterisation study; also causes pronounced binding defect to both type I and III collagen; OMIM 613160.0042 — another A3-domain variant in the same collagen-binding groove. Compound heterozygosity of two A3-domain defects (e.g. W1745C on one allele and S1783A or another A3 variant on the other) would be expected to produce near-complete loss of collagen-binding activity and a more severe bleeding phenotype, though no published case of such a combination has been described. The index patient carrying W1745C was compound heterozygous with R760H, a type 1 VWD variant in the D3 domain — this combination reduced VWF:CB/VWF:Ag to 0.3 — suggesting that heterozygous W1745C alone may not fully account for all bleeding symptom severity when other VWF variants are co-inherited. ABO blood group (O type lowers VWF levels ~25%) is the standard VWF modifier, but ABO effects operate through VWF clearance rate, not collagen binding, so the ABO interaction is less clinically relevant for this qualitative A3-domain defect than it is for quantitative VWD variants.

Interleukin-10 (IL-10) is the immune system's master anti-inflammatory cytokine — the molecular signal that tells an activated immune response to stand down. When IL-10 production is reduced, inflammatory reactions in the gut, joints, and other tissues run longer and harder than they should. rs3024505 sits approximately 5 kilobases downstream of the IL10 gene's 3' end on chromosome 1q32.1¹¹ chromosome 1q32.1
The long arm of chromosome 1, a region with dense immune gene content and one of the most robustly replicated IBD susceptibility loci in the human genome. It is the lead GWAS signal at the IL10 locus for inflammatory bowel disease and has been associated with systemic lupus erythematosus, Sjögren's syndrome, and other autoimmune conditions.

IL10 is encoded on the minus (reverse) strand of chromosome 1. Genome files report alleles on the plus strand — so while published papers describe this as a C/T polymorphism (coding-strand notation), plus-strand genome files use G and A. The common G allele corresponds to the protective C allele in papers; the risk A allele is what papers call the T allele. All genotype keys here use plus-strand notation as reported by genome files.

The Mechanism

rs3024505 lies within an enhancer element²² enhancer element
A non-coding DNA sequence that boosts the transcriptional activity of nearby genes; enhancers can act over long distances by looping toward gene promoters that augments IL10 promoter activity, particularly in B cells. The common G allele (coding-strand C) creates a functional binding site for the transcription factor STAT3, which drives IL10 expression when immune cells are activated. The risk A allele (coding-strand T) disrupts this STAT3 binding site — luciferase reporter assays in stimulated pro-B cell lines confirmed a significant reduction in enhancer activity for the A variant compared to G.

This mechanism explains why rs3024505 is an expression quantitative trait locus (eQTL)³³ expression quantitative trait locus (eQTL)
A genetic variant that predicts the expression level of a nearby gene, confirmed in multiple immune cell types for IL10: carriers of the A allele produce less IL-10 per stimulated B cell. Lower IL-10 shifts the immune environment toward a more pro-inflammatory baseline. In the gut mucosa, inadequate IL-10 allows the normal commensal microbiome to trigger unresolved inflammatory responses — the fundamental driver of both Crohn's disease and ulcerative colitis. In systemic autoimmunity, impaired B cell IL-10 production removes a critical brake on autoreactive immune cell activation.

The Evidence

rs3024505 was first identified as a genome-wide significant UC susceptibility locus in the landmark 2008 GWAS at chromosome 1q32.1 that implicated IL10 in inflammatory bowel disease. The lead signal pointed directly to the IL10 downstream region as central to IBD pathogenesis.

A Danish case-control study of 336 CD patients, 498 UC patients, and 779 healthy controls⁴⁴ of 336 CD patients, 498 UC patients, and 779 healthy controls
Holt et al. 2010, The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohn's disease in a Danish case-control study, BMC Medical Genetics provided the clearest genotype-level data. Heterozygous CT carriers had OR = 1.31 for CD (p = 0.07) and OR = 1.34 for UC (p = 0.02). Homozygous TT carriers (corresponding to AA on the plus strand) showed substantially higher risk: OR = 2.48 for CD (95% CI 1.27–4.84, p = 0.01) and OR = 2.31 for UC (95% CI 1.27–4.20, p = 0.01). The combined CT+TT group reached OR = 1.40 for CD (p = 0.02) and OR = 1.43 for UC (p = 0.004). The T allele frequency in Danish controls was 18%.

A meta-analysis of 13 studies covering 8,552 IBD cases and 12,830 controls⁵⁵ of 13 studies covering 8,552 IBD cases and 12,830 controls
Gu et al. 2021, Association between IL-10 rs3024505 and susceptibility to inflammatory bowel disease: A systematic review and meta-analysis, Cytokine confirmed strong and consistent association across European populations: OR = 1.37 (95% CI 1.30–1.45) under the allelic model, OR = 2.06 (95% CI 1.74–2.45) under the recessive model, and OR = 2.25 (95% CI 1.89–2.67) for homozygous TT vs. CC (all p < 0.00001).

A Serbian case-control study of 107 CD patients, 99 UC patients, and 255 controls⁶⁶ of 107 CD patients, 99 UC patients, and 255 controls
Simovic et al. 2016, Downstream IL10 polymorphism associated with Crohn's disease in Serbian IBD patients, Inflammatory Bowel Diseases replicated the CD association and added a clinical nuance: carriers of the protective C allele had significantly increased risk of anemia and stricturing or penetrating disease behavior, illustrating how this locus influences not just susceptibility but also disease phenotype.

Beyond IBD, rs3024505 has been associated with systemic lupus erythematosus and Sjögren's syndrome (OR = 1.52, p = 0.025 for Sjögren's susceptibility), consistent with the variant's role in B cell IL-10 regulation across multiple autoimmune contexts.

The 2024 mechanistic study using reporter assays and chromatin immunoprecipitation in human B cell lines⁷⁷ using reporter assays and chromatin immunoprecipitation in human B cell lines
Uvarova et al. 2024, Autoimmunity-Associated SNP rs3024505 Disrupts STAT3 Binding in B Cells, Leading to IL10 Dysregulation, International Journal of Molecular Sciences provided the first direct functional explanation: the variant creates or destroys a STAT3 recognition sequence, giving rs3024505 a clear molecular mechanism — rare for a non-coding GWAS SNP.

Practical Actions

The A allele's functional effect on IL-10 production is concentrated in B cells but has downstream consequences for the entire mucosal and systemic immune environment. Anti-inflammatory nutritional strategies that upregulate IL-10 through independent pathways — particularly omega-3 fatty acids (EPA/DHA) and vitamin D — can partially compensate. EPA and DHA stimulate IL-10 production in macrophages and regulatory T cells via PPAR-γ activation; vitamin D drives IL-10 expression in Treg cells independently of STAT3. Neither substitutes for STAT3-driven B cell IL-10, but they reduce the overall inflammatory burden that low IL-10 producers carry.

For anyone with the AA genotype and gut symptoms, early gastroenterological evaluation is warranted. The diagnostic delay for IBD averages 1–3 years, and genetic risk awareness can prompt earlier endoscopic investigation before complications develop. Calprotectin testing offers a non-invasive first screen to distinguish gut inflammation from functional disorders.

Interactions

rs3024505 operates in parallel with the IL10 promoter haplotype system (rs1800896, rs1800871, rs1800872) and the intronic variant rs3024491, each of which independently regulates IL10 transcription from different regulatory elements. Carriers of both the downstream A allele at rs3024505 and a low-producing promoter haplotype face stacked reductions in IL-10 from multiple regulatory levels — a combined low-producer state that is likely additive for IBD risk and autoimmune susceptibility, though direct compound studies are limited.